The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain

被引:26
|
作者
Haduch, Anna [1 ]
Bromek, Ewa [1 ]
Daniel, Wladyslawa A. [1 ]
机构
[1] Polish Acad Sci, Inst Pharmacol, PL-31343 Krakow, Poland
关键词
Brain and liver microsome; cDNA-expressed CYP2D; Antidepressant; Neuroleptic; Chronic treatment; (Rat CYP2D); CHRONIC NICOTINE TREATMENT; IN-VITRO; MAJOR DEPRESSION; MESSENGER-RNA; CLINICAL PHARMACOKINETICS; TRICYCLIC ANTIDEPRESSANTS; CELLULAR-DISTRIBUTION; NEUROACTIVE STEROIDS; NONSPECIFIC-BINDING; METABOLIZING ENZYME;
D O I
10.1016/j.ejphar.2010.10.077
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the study was to investigate the influence of selected antidepressants and neuroleptics on the protein level and activity of cytochrome P450 2D (CYP2D) in rat brain. The obtained results showed that imipramine, fluoxetine, nefazodone, thioridazine and perazine, added to brain microsomes of control rats, inhibited CYP2D activity to a lower extent (K-i = 255-485 mu M) than when added to liver microsomes (K-i = 1-45 mu M), which may result from their stronger affinity for liver CYP2D2 (K-i = 2.7 and 1.25 mu M for imipramine and fluoxetine, respectively) than for brain CYP2D4 (K-i = 25 and 10 mu M for imipramine and fluoxetine, respectively), as well as from their high non-specific binding in brain microsomes. Two-week treatment with fluoxetine evoked decreases in the level and activity of CYP2D in the striatum and the nucleus accumbens. In contrast, fluoxetine increased CYP2D expression in the cerebellum, while nefazodone considerably enhanced the activity (but not the protein level) of CYP2D in the truncus cerebri. Imipramine and mirtazapine (active in the liver) did not affect brain CYP2D. Chronic thioridazine decreased CYP2D activity in the substantia nigra and nucleus accumbens, but significantly increased that activity in the striatum and cerebellum. Clozapine significantly enhanced CYP2D activity in the truncus cerebri. In conclusion, psychotropics influence CYP2D in the brain, but their effect is different than in the liver and depends on the cerebral structure. The observed psychotropics-brain CYP2D interactions may be important for the metabolism of neurosteroids and monoaminergic neurotransmitters, and for the local biotransformation of drugs. (c) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 50 条
  • [31] Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib
    Xu, HY
    Xie, ZY
    Zhang, P
    Sun, J
    Chu, FM
    Guo, ZR
    Zhong, DF
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (03) : 372 - 380
  • [32] Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib
    Hai-yan Xu
    Zhi-yong Xie
    Peng Zhang
    Jin Sun
    Feng-ming Chu
    Zong-ru Guo
    Da-fang Zhong
    Acta Pharmacologica Sinica, 2006, 27 : 372 - 380
  • [33] Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs
    Stingl, J.
    Viviani, R.
    JOURNAL OF INTERNAL MEDICINE, 2015, 277 (02) : 167 - 177
  • [34] Cytochrome P450 2D6 (CYP2D6) activity in relation to the antitussive effect of dextromethorphan
    Abdul-Manap, R
    Wright, CE
    Rostami-Hodjegan, A
    Meller, S
    Lennard, MS
    Morice, AH
    Tucker, GT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (05) : 586 - 587
  • [35] The unique regulation of brain cytochrome p450 2 (CYP2) family enzymes by drugs and genetics
    Miksys, S
    Tyndale, RF
    DRUG METABOLISM REVIEWS, 2004, 36 (02) : 313 - 333
  • [36] Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms. (vol 10, 3472, 2021)
    Danek, Przemyslaw J.
    Daniel, Wladyslawa A.
    CELLS, 2024, 13 (24)
  • [37] Psychotropic medications and cytochrome P450 2D6 pharmacokinetic considerations in the elderly
    Shulman, RW
    Ozdemir, V
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1997, 42 : S4 - S9
  • [38] Cytochrome P450 2D6
    Owen, Ryan P.
    Sangkuhl, Katrin
    Klein, Teri E.
    Altman, Russ B.
    PHARMACOGENETICS AND GENOMICS, 2009, 19 (07): : 559 - 562
  • [39] INHIBITION OF HUMAN CYTOCHROME P450 2D6 (CYP2D6) BY METHADONE
    WU, D
    OTTON, SV
    SPROULE, BA
    BUSTO, U
    INABA, T
    KALOW, W
    SELLERS, EM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 35 (01) : 30 - 34
  • [40] Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19
    Hichiya, H
    Kuramoto, S
    Yamamoto, S
    Shinoda, S
    Hanioka, N
    Narimatsu, S
    Asaoka, K
    Miyata, A
    Iwata, S
    Nomoto, M
    Satoh, T
    Kiryu, K
    Ueda, N
    Naito, S
    Tucker, GT
    Ellis, SW
    BIOCHEMICAL PHARMACOLOGY, 2004, 68 (01) : 165 - 175